Pyridostigmine bromide

Full Generic Medicine Info
Dosage/Direction for Use

Myasthenia gravis
Adult: 30-120 mg in divided doses, up to a total daily dose of 0.3-1.2 g.
Child: <6 yr Initially, 30 mg; 6-12 yr Initially, 60 mg. Doses are repeated throughout the day up to a usual total daily dose of 30-360 mg, w/ increments of 15-30 mg daily until a satisfactory response is obtained.
Renal impairment: Lower initial dose may be needed, titrate to desired effect.

Paralytic ileus and postoperative urinary retention
Adult: 60-240 mg daily.
Child: 15-60 mg daily.
Renal impairment: Lower initial dose may be needed, titrate to desired effect.

Reversal of neuromuscular blockade
Adult: 0.1-0.25 mg/kg (approx 10-20 mg), w/ or preceded by atropine sulfate.
Renal impairment: Lower initial dose may be needed, titrate to desired effect.
Should be taken with food.
Mechanical GI or urinary obstruction.
Special Precautions
Patient w/ bronchial asthma, COPD, bradycardia, cardiac arrhythmias, vagotonia, peptic ulcer, epilepsy or parkinsonism, hyperthyroidism. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor cholinergic reaction particularly in IV admin.
Adverse Reactions
Nausea, vomiting, diarrhoea, increased peristalsis and bronchial secretions, miosis, excessive salivation and sweating, abdominal cramps, bradycardia, bronchospasm, skin rash, muscle spasm, fasciculation, muscle weakness.
Potentially Fatal: Resp paralysis, cardiac arrest, pulmonary oedema.
Symptoms: Cholinergic crisis characterised by severe muscarinic (e.g. nausea and vomiting, diarrhoea) and nicotinic symptoms (e.g. muscle weakness); electrolyte abnormalities. CNS symptoms (e.g. agitation, restlessness, confusion) may occur in extremely high doses. Death may result from CV and resp failure. Management: Maintain adequate respiration. Artificial respiration should be instituted in severe resp depression. Administer 1-4 mg of atropine sulfate IV, w/ additional doses given every 5-30 min as needed.
Drug Interactions
May exacerbate night vision problems w/ anti-glaucoma drugs. Antagonises the effect of non-depolarising muscle relaxants (e.g. pancuronium, vecuronium). Prolongs the effect of depolarising muscle relaxants (e.g. suxamethonium).
Pyridostigmine bromide facilitates impulse transmission across the myoneural junction by inhibiting the destruction of acetylcholine by acetylcholinesterase. It also has direct cholinomimetic effect on skeletal muscles.
Onset: 30-45 min (oral); w/in approx 15 min (IM); 2-5 min (IV).
Duration: 3-6 hr (oral); 2-3 hr (IV).
Absorption: Poorly absorbed from the GI tract. Bioavailability: 10-20% (oral). Time to peak plasma concentration: Approx 1-3 hr (oral).
Distribution: Crosses the placenta and enters breast milk; poor penetration into CNS. Volume of distribution: Approx 19 L.
Metabolism: Undergoes hepatic metabolism and hydrolysis by cholinesterases.
Excretion: Via urine as unchanged drug and metabolites. Elimination half-life: 3 hr (oral); approx 1.5 hr (IV).
Intravenous: Store at 25°C. Protect from light. Oral: Store at 25°C. Protect from light.
CIMS Class
Antidotes, Detoxifying Agents & Drugs Used in Substance Dependence / Neuromuscular Disorder Drugs / Other Drugs Acting on the Genito-Urinary System
Disclaimer: This information is independently developed by CIMS based on pyridostigmine bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in